Open an account

Corgi IP Licensing & Royalties ETF

PTNT · ETF

$24.15−$0.1209 (−0.50%)TodayMarket closed ·
No price history for this range.

About PTNT

PTNT was created on 2026-05-06 by Corgi. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 1.1m in AUM and 31 holdings. PTNT seeks capital appreciation through a portfolio of companiesinvolved in intellectual property (IP) monetization, generating significant revenue through licensing, royalties, franchise fees, and other IP-based income streams.

Issuer
Corgi
Expense ratio
0.35%
Assets under management
$1.10M
Inception
May 6, 2026
Asset class
Equity
Website
corgifunds.com

PTNT key statistics

Price-earnings ratio
0.00
Average volume
61
Volume
11
Open price
$24.27
High today
$24.15
Low today
$24.15
52 Week high
$27.92
52 Week low
$24.18

Corgi IP Licensing & Royalties ETF (PTNT) at a glance

As of Oct 23, 2026, Corgi IP Licensing & Royalties ETF (PTNT) shares are priced at $24.15, giving the company a price-to-earnings ratio of 0.00.

Volume so far is 11 shares, below the average of 61 shares a day.

Over the past year Corgi IP Licensing & Royalties ETF has ranged from $24.18 to $27.92, and now sits -1% of the way up that range.

PTNT news

  • Press releasePRNewswire

    Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity

  • Press releasePRNewswire

    Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering

  • Press releasePRNewswire

    Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim

  • Press releasePRNewswire

    Palatin Announces 1-for-50 Reverse Stock Split

  • Press releasePRNewswire

    Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity

  • Press releasePRNewswire

    Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update

  • Press releasePRNewswire

    Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025

  • Press releasePRNewswire

    Palatin Technologies Announces Closing of Reduced Public Offering

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.